

Certificate of Analysis

MKK6/SKK3 (4–end), active
(Recombinant enzyme expressed in *E.coli* cells)
Item # 14-303, 14-303-K, 14-303M
Parent Lot # 25730U

The data presented in this document apply to the parent lot shown above and to all pack sizes derived from subsequent vialling runs of this parent lot. An alphabetical suffix after the parent lot number is used to denote each vialling run.

Product Description: Recombinant human MKK6/SKK3, residues 4–end, containing an *N*-terminal maltose binding protein tag, expressed in *E.coli* cells. Purified using amylose agarose. Purity 95% by SDS-PAGE and Coomassie staining. MW = 82kDa.

Specific Activity (Parent lot# 25730U): 1940U/mg, where one unit of MKK6, active activity is defined as the amount of MKK6 which activates 2 μ M inactive SAPK2a by 1 unit per minute at 30°C using 100 μ M ATP. One unit of SAPK2a activity is defined as 1nmole of phosphate incorporated into 0.33mg/ml myelin basic protein per minute at 30°C with a final ATP concentration of 100 μ M.

Formulation: 0.459mg/ml of enzyme in 50mM Tris/HCl pH7.5, 150mM NaCl, 0.03% Brij-35, 0.1mM EGTA, 0.2mM PMSF, 1mM benzamidine, 0.1% 2-mercaptoethanol, 270mM sucrose. Frozen solution.

Storage and Stability: On receipt of material store at -70°C. Unopened reagent is stable for a minimum of 1 year from date of shipment when stored at recommended storage temperature. Avoid repeat freeze/thaw cycles. For maximum recovery of product, centrifuge original vial prior to removing the cap.



Handling Recommendations: Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into pre-chilled micro-centrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70°C..

FOR IN VITRO RESEARCH USE ONLY
NOT FOR USE IN HUMANS OR ANIMALS

Quality Control Testing

Kinase Assay: 16–80ng of this lot of enzyme phosphorylated, 2 μ M inactive SAPK2a in the assay described on page two.

MS Tryptic Fingerprint: Confirmed identity as MKK6 with the translated sequence listed on page three.



Certificate of Analysis

Kinase Assay Protocol

Stock Solutions:

1. **5 x SAPK2a Activation Buffer:** 500mM Tris/HCl pH7.5, 1mM EGTA, 1mM Na₃VO₄, 1% 2-mercaptoethanol, 10mg/ml BSA.
2. **10 x Reaction Buffer:** 250mM Tris/HCl pH7.5, 1mM EGTA.
3. **SAPK2a unactive:** Use a final assay concentration of 0.28mg/ml (2µM). Make up a 2.8mg/ml stock. Use 2.5 µl of stock per assay point.
4. **Myelin Basic Protein (MBP):** Use a final assay concentration of 0.33mg/ml. Make up a 3.33mg/ml stock. Use 2.5 µl of stock per assay point.
5. **MKK6 (w/t), active:** Dilute with 50mM Tris/HCl pH7.5, 0.1mM EGTA, 0.1mM Na₃VO₄, 1mg/ml BSA. Use 16–80ng per assay point.
6. **Stage One 5 x Mg/ATP:** 50mM magnesium acetate, 0.5mM ATP.
7. **[γ-³³P]ATP:** 2.5 x magnesium acetate/[γ-³³P]ATP cocktail: 25mM MgAc and 0.25mM ATP to which is added [γ-³³P]ATP (specific activity approximately 500 - 800cpm/pmol as required.)

Assay Procedure:

Stage One: *Activation of SAPK2a*

1. Add 5µl of SAPK2a reaction buffer.
2. Add 2.5µl of **SAPK2a unactive**.
3. Add **2.5µl (16–80ng) of MKK6 (w/t), active**.
4. Add 10µl of dH₂O.
5. Add 5µl of stage one Mg/ATP.
6. Incubate for 15 minutes at 30°C. Immediately transfer **5µl** into **Stage Two**.

Stage Two: *Phosphorylation of MBP by activated MKK6 (w/t)*

1. Add 2.5µl of reaction buffer.
2. Add 2.5µl of **MBP**.
3. Add **5µl** of **Stage One** reaction product.
4. Add 5µl of dH₂O.
5. Add 10µl of diluted [γ-³³P]ATP mixture.
6. Incubate for 15 minutes at 30°C.
7. Transfer a 20µl aliquot onto the centre of a 2 cm x 2 cm **P81** paper square.
8. Wash the assay squares twice for 5 minutes with 75mM phosphoric acid.
9. Wash the assay squares once for 2 minutes with acetone.
10. Transfer the assay squares to a scintillation vial and add 1ml of scintillation cocktail.
11. Read in a scintillation counter. Compare cpm of enzyme samples with cpm of control samples that contain all assay components plus 1µl of 30% phosphoric acid.

Certificate of Analysis

MKK6 Sequence Information

<u>Protein</u>	Human MKK6
<u>Tags</u>	N-terminal maltose-binding protein domain
<u>Native sequence</u>	S396 of the fusion protein is equivalent to S4 of human MKK6
<u>Accession number</u>	EMBL U39657

Recombinant MKK6 amino acid sequence:

```

1 MKTEEGKLV I WINGDKGYNG LAEVGKKFEK DTGIKVTVEH PDKLEEKFPQ VAATGDGPDI
61 IFWAHDRFGG YAQSGLLAEI TPKAFQDKL YPFTWDAVRY NGKLIAYPIA VEALS LIYNK
121 DLLPNPPKTW EEIPALDKEL KAKGKSALMF NLQEPYFTWP LIAADGGYAF KYENGKYDIK
181 DVGVDNAGAK AGLTFLVDLI KNKHMNADTD YSIAEAAFNK GETAMTINGP WAWSNIDTSK
241 VNYGVTVLPT FKGQPSKPFV GVLSAGINAA SPNKELAKEF LENYLLTDEG LEAVNKDKPL
301 GAVALKSYEE ELAKDPRIAA TMENAQKGEI MPNIPQMSAF WYAVRTAVIN AASGRQTVDE
361 ALKDAQTNSS SNNNNNNNNN NLGIEGRISE FGSSRSKGKK RNPGLKIPKE AFEQPQTSST
421 PPRDLDSKAC ISIGNQNFV KADDLEPIME LGRGAYGVVE KMRHVPSGQI MAVKRIRATV
481 NSQEQKRLLM DLDISMRTVD CPFTVTFYGA LFREGDVWIC MELMDTSLDK FYKQVIDKGQ
541 TIPEDILGKI AVSIVKALEH LHSKLSVIHR DVKPSNVLIN ALGQVKMCFD GISGYLVDSV
601 AKTIDAGCKP YMAPERINPE LNQKGYSVKS DIWSLGITMI ELAILRFPYD SWGTPFQQLK
661 QVVEEPSQPL PADKFSAEFV DFTSQCLKKN SKERPTYPEL MQHPFFTLHE SKGTDVASFV
721 KLILGD

```

Recombinant MKK6 nucleotide sequence:

```

1 atgaaaactg aagaaggtaa actggtaatc tggattaacg gcgataaagg ctataacggt
61 ctcgctgaag tccgtaagaa attcgagaaa gataccggaa ttaaagtcac cgttgagcat
121 ccgataaac tggagagaa attcccacag gttgcggcaa ctggcgatgg ccctgacatt
181 atcttctggg cacacgaccg ctttgggtggc tacgctcaat ctggcctggt ggctgaaatc
241 acccggaca aagcgttcca ggacaagctg tatccgttta cctgggatgc cgtacgttac
301 aacggcaagc tgattgctta cccgatcgct gttgaagcgt tatcgctgat ttataacaaa
361 gatctgctgc cgaaccgcgc aaaaacctgg gaagagatcc cggcgctgga taaagaactg
421 aaagcgaaag gtaagagcgc gctgatgttc aacctgcaag aaccgtactt cacctggccg
481 ctgattgctg ctgacggggg ttatgctgctc aagtatgaaa acggcaagta cgacattaaa
541 gacgtgggcg tggataacgc tggcgcgaaa gcggtctgta ctttctggtg tgacctgatt
601 aaaaacaaac acatgaatgc agacaccgat tactccatcg cagaagctgc ctttaataaa
661 ggcgaaacag cgatgaccat caacggcccg tgggcatggt ccaacatcga caccagcaaa
721 gtgaattatg gtgtaacggg actgccgacc ttcaagggtc aaccatccaa accggttcgtt
781 ggcgtgctga gcgcaggtat taacgcgcgc agtccgaaca aagagctggc aaaagagttc
841 ctgaaaaact atctgctgac tgatgaaggt ctggaagcgg ttaataaaga caaacgctg
901 ggtgccgtag cgctgaagtc ttacaggaaa gagttggcga aagatccacg tattgcccgc
961 accatggaaa acgcccagaa aggtgaaatc atgccgaaca tcccgcagat gtcgctttc
1021 tggatgccc tgcgtactgc ggtgatcaac gccgccagcg gtcgctcagc tgcgatgaa
1081 gccctgaaag acgcgagac taattcgagc tcgaacaaca acaacaataa caataacaac
1141 aacctcggga tcgaggggaa gatttcagaa ttcggatcct ctagatcgaa aggcaagaag
1201 cgaaaccctg gccttaaaat tccaaaagaa gcatttgaac aacctcagac cagttccaca
1261 ccacctcgag atttagactc caaggcttgc atttctattg gaaatcagaa ctttgagggtg
1321 aaggcagatg acctggagcc tataatggaa ctgggacgag gtgctgacgg ggtggtggag
1381 aagatgctgc acgtgccagc cgggcagatc atggcagtg aagcggatcc agccacagta
1441 aatagccagg aacagaaacg gctactgatg gatttggata tttccatgag gacggtggac
1501 tgtccattca ctgtcacctt ttatggcgca ctgtttcggg agggatgatg gtggatctgc
1561 atggagctca tggatacatc actagataaa ttctacaac aagttattga taaaggccag
1621 acaattccag aggacatctt agggaaaata gcagtttcta ttgtaaaagc attagaacat
1681 ttacatagta agctgtctgt cattcacaga gacgtcaagc ctttctaatgt actcatcaat

```

Certificate of Analysis

```
1741 gctctcggtc aagtgaagat gtgcgattht ggaatcagtg gctacttggt ggactctggt
1801 gctaaaacaa ttgatgcagg ttgcaaacca tacatggccc ctgaaagaat aaaccagag
1861 ctcaaccaga agggatacag tgtgaagtct gacatttggg gtctgggcat cacgatgatt
1921 gagttggcca tccttcgatt tccctatgat tcatggggaa ctccatttca gcagctcaaa
1981 caggtggtag aggagccatc gccacaactc ccagcagaca agttctctgc agagtttggt
2041 gactttacct cacagtgctt aaagaagaat tccaaagaac ggcctacata cccagagcta
2101 atgcaacatc ctttttcac cctacatgaa tccaaaggaa cagatgtggc atcttttgta
2161 aaactgattc ttggagacta a
```

Reviewed and approved by site quality representative.

Unless otherwise stated in our catalogue or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

© 2014 Eurofins Pharma Discovery Services UK Limited is an independent member of Eurofins Discovery Services.